Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 237
- Registration Number
- NCT00191243
- Locations
- 🇫🇮
For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland
Long-Term, Open Label Atomoxetine Study
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-01-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1553
- Registration Number
- NCT00190684
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, South Yorkshire, United Kingdom
Open Label Phase III Duloxetine Study for Stress Urinary Incontinence
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 363
- Registration Number
- NCT00191204
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours EST), or speak with your personal physician., Peterborough, United Kingdom
Local Registration Trial in China Humalog Mix 50
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-07-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00191581
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Guangzhou, China
Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 121
- Registration Number
- NCT00191906
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vught, Netherlands
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-05-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT00190749
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States
Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-03-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT00191269
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 147
- Registration Number
- NCT00191854
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 64
- Registration Number
- NCT00191139
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Suwon-City, Korea, Republic of
Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 151
- Registration Number
- NCT00191945
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain